Dexamethasone KRKA tablets 20 mg No. 10

Dexamethasone KRKA tablets are indicated for the palliative treatment of tumors.

Composition

Active ingredient: dexamethasone;

1 tablet contains 20 mg or 40 mg of dexamethasone;

Excipients: lactose monohydrate, corn starch, colloidal silicon dioxide, magnesium stearate.

Contraindication

Method of application

Dexamethasone should be taken with or immediately after food to minimize gastrointestinal irritation. Drinks containing alcohol or caffeine should be avoided.

The tablets can be divided into equal parts and provide additional doses of 2 mg and 10 mg to make the tablet easier for the patient to swallow. When alternate-day therapy is not possible, the total daily dose of glucocorticoids can usually be administered as a single morning dose, however some patients require divided daily doses of glucocorticoids.

Application features

Pregnant women

Dexamethasone during pregnancy, especially in the first trimester, should be prescribed only if the benefit outweighs the risks to the mother and child.

Children

The initial dose range of dexamethasone is 0.08-0.3 mg/kg/day or 2.5 mg-10 mg/m2 of body surface area/day in 3-4 divided doses.

Drivers

It is forbidden to drive vehicles, operate machinery, or perform dangerous tasks.

Overdose

Symptoms: Acute toxicity and/or fatalities following GCS overdose have been reported rarely.

Overdose or prolonged use may increase the side effects of glucocorticoids.

Treatment. There is no antidote. Treatment is symptomatic and supportive. It is planned to reduce the dosage of dexamethasone or slowly discontinue it, if possible.

Side effects

The frequency of expected adverse reactions correlates with the relative activity of the substance, dose, time of administration and duration of treatment. The risk of side effects is low during short-term therapy, provided that the dosage recommendations are followed and patients are carefully monitored.

Common side effects of short-term dexamethasone treatment (days/weeks) include weight gain, psychiatric disorders, impaired glucose tolerance, and transient adrenal insufficiency. Long-term dexamethasone treatment (months/years) typically causes central obesity, skin fragility, muscle atrophy, osteoporosis, growth retardation, and long-term adrenal insufficiency.

Interaction

Before using Dexamethasone KRKA in combination with any other medicine, you should read the instructions for use of this medicine.

Thalidomide: Special attention should be paid to concomitant use with thalidomide, as cases of toxic epidermal necrolysis have been reported.

Chloroquine, hydroxychloroquine, and mefloquine. Increased risk of myopathy and cardiomyopathy.

Cholinesterase inhibitors: Concomitant use of cholinesterase inhibitors and corticosteroids may result in severe muscle weakness in patients with myasthenia gravis. If possible, cholinesterase inhibitors should be discontinued at least 24 hours before starting corticosteroid therapy.

Storage conditions

The medicinal product does not require special temperature storage conditions.

Store in the original packaging to protect from light and moisture.

Keep out of reach of children.

Shelf life - 2 years.